Anti-diabetic medications and risk of primary liver cancer in persons with type II diabetes

British Journal of Cancer

Volumn 111, Issue 9, 2014, Pages 1710-1717

  Hagberg, K W ^a   Mcglynn, K A ^b   Sahasrabuddhe, V V ^b   Jick, S ^a  

^a BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

insulin; liver cancer; metformin; oral hypoglycaemic

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; HEMOGLOBIN A1C; INSULIN; METFORMIN; PARACETAMOL; SULFONYLUREA; ANTIDIABETIC AGENT;

ADULT; AGED; ALCOHOLISM; ARTICLE; BODY MASS; CANCER RISK; CASE CONTROL STUDY; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DRUG EXPOSURE; DRUG USE; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CANCER; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY TUMOR; SMOKING; ADOLESCENT; CHEMICALLY INDUCED; CHILD; COMPLICATION; DIABETES MELLITUS, TYPE 2; EPIDEMIOLOGY; FACTUAL DATABASE; FOLLOW UP; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RISK FACTOR; UNITED KINGDOM; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHILD; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; HYPOGLYCEMIC AGENTS; LIVER NEOPLASMS; MALE; METFORMIN; MIDDLE AGED; PROGNOSIS; RISK FACTORS; YOUNG ADULT;

EID: 84908569769     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.447     Document Type: Article

References (25)

1. Adami HO, Chow WH, Nyren O, Berne C, Linet MS, Ekbom A, Wolk A, McLaughlin JK, Fraumeni Jr. JF (1996) Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst 88: 1472-1477.
2. Bowker SL, Majumdar SR, Veugelers P, Johnson JA (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29(2): 254-258.
3. Chen HP, Shieh J, Chang CC, Chen TT, Lin JT, Wu MS, Lin JH, Wu CY (2013) Metformin decreases hepatocellular carcinoma risk in a dosedependent manner: Population-based and in vitro studies. Gut 62(4): 606-615.
4. Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, Gandini S (2010) Metformin and cancer risk in diabetic patients: A systematic review and meta-Analysis. Cancer Prev Res (Phila) 3(11): 1451-1461.
5. Donadon V, Balbi M, Mas MD, Casarin P, Zanette G (2010) Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int 30(5): 750-758.
6. El-Serag HB, Hampel H, Javadi F (2006) The association between diabetes and hepatocellular carcinoma: A systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 4: 369-380.
7. Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pallegrini F, Nicolucci A (2013) Metformin therapy and risk of cancer in patients with type 2 diabetes: Systematic review. PLoS One 8(8): E71583.
8. Gallagher EJ, LeRoith D (2011) Diabetes, cancer, and metformin: Connections of metabolism and cell proliferation. Ann N Y Acad Sci 1243: 54-68.
9. Hassan MM, Curley SA, Li D, Kaseb A, Davila M, Abdalla EK, Javel M, Moghazy DM, Lozano RD, Abbruzzese JL, Vauthey JN (2010) Association of diabetes duration and diabetes treatment with risk of hepatocellular carcinoma. Cancer 116(8): 1938-1943.
10. International Agency for Research on Cancer (2014) Cancer Incidence in Five Continents, Vol. X (electronic versions) Lyon. http://ci5.iarc.fr/last accessed on January 22.
11. Jick H, Jick SS, Derby LE (1991) Validation of information recorded on general practitioner based computerized data resource in the United Kingdom. BMJ 302: 766-768.
12. Jick H, Jick SS, Derby LE, Vasilakis C, Myers MW, Meier CR (1997) Calcium channel blockers and risk of cancer. Lancet 349: 525-528.
13. Jick H, Terris BZ, Derby LE, Jick SS (1992) Further validation of information recorded on a general practitioner based computerized data resource in the United Kingdom. Pharmacoepidemiol Drug Saf 1: 347-349.
14. Jick SS, Kaye JA, Vasilakis-Scaramozza C, Garcia Rodriguez LA, Ruigomez A, Meier CR, Schlienger RG, Black C, Jick H (2003) Validity of the general practice research database. Pharmacotherapy 23: 686-689.
15. Kawaguchi T, Taniguchi E, Morita Y, Shirachi M, Tateishi I, Nagata E, Sata M (2010) Association of exogenous insulin or sulphonylurea treatment with increased incidence of hepatoma in patients with hepatitis C virus infection. Liver Int 30(3): 479-486.
16. Lawson DH, Sherman V, Hollowell J for the Scientific and Ethical Advisory Group (1998) The General Practice Research Database. Q J Med 91: 445-452.
17. Lee M, Hsu C, Wahlqvist ML, Tsai NH, Chang YH, Huang YC (2011) Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic incidences in Taiwanese: A representative population prospective cohort study of 800,000 individuals. BMC Cancer 11: 20.
18. McGlynn KA, London WT (2011) The global epidemiology of hepatocellular carcinoma: Present and future. Clin Liver Dis 15: 223-243.
19. NICE (2014) Pathways, Managing type 2 diabetes. National Institute for Health and Care Excellence (NICE): United Kingdom. http://pathways. nice.org.uk/pathways/diabetes#path=view%3A/pathways/diabetes/managing-Type-2-diabetes.xml&content=closelast accessed on January 28.
20. Nkontchou G, Cosson E, Aout M, Mahmoudi A, Bourcier V, Charif I, Ganne-Carie N, Grando-Lemarie V, Vicante E, Trinchet JC, Beaugrand M (2011) Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. J Clin Endocrinol Metab 96(8): 2601-2608.
21. Oliveria SA, Koro CE, Yood MU, Sowell M (2008) Cancer incidence among patients treated with antidiabetic pharmacotherapy. Diabetes Metab Syndr: Clin Res Rev 2(1): 47-57.
22. Ruiter R, Visser L, van Herk-Sukel MPP, Coebergh JW, Haak HR, Geelhoed-Duij Vestin PH, Straus SM, Herings RM, Stricker BH (2012) Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: Results from a large population-based follow-up study. Diabetes Care 35(1): 119-124.
23. Singh S, Singh PP, Singh AG, Murad MH, Sanchez W (2013) Anti-diabetic medications and the risk of hepatocellular cancer: A systematic review and meta-Analysis. Am J Gastroenterol 108: 881-891.
24. Wang C, Wang X, Gong G, Ben Q, Qui W, Chen Y, Li G, Wang L (2012) Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: A systematic review and meta-Analysis of cohort studies. Int J Cancer 130: 1639-1648.
25. Zhang H, Gao C, Fang L, Zhao HC, Yao SK (2013) Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: A meta-Analysis. Scand J Gastroenterol 48: 78-87.